Navigation Links
MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
Date:9/7/2010

MOUNTAIN VIEW, Calif., Sept. 7 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following healthcare conferences in September:

Morgan Stanley Global Healthcare Conference

Tuesday, September 14, at 11:30 a.m. ET in New York

Stifel Nicolaus 2010 Healthcare ConferenceWednesday, September 15, at 2:05 p.m. ET in Boston

UBS Global Life Sciences Conference

Tuesday, September 21, at 9:00 a.m. ET in New York

A live webcast of the events will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours following the presentation.

In addition, the Company will be presenting its LEVADEX™ orally inhaled migraine therapy Phase 3 data at the American Neurological Association's 135th Annual Meeting on Monday, September 13, at 1:00 p.m. in San Francisco.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com. CONTACTS:Nicole Foderaro WCG(415) 946-1058nfoderaro@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
2. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
3. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
4. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
6. Pfizer to Acquire FoldRx Pharmaceuticals
7. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
8. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
9. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
10. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
11. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... SAN FRANCISCO , March 29, 2017 /PRNewswire/ ... an option agreement with Bionure Farma, S.L. for ... BN201 and to BN119 in the field of ... million plus sales-based royalties. The agreement provides ... stage assets with a differentiated product profile. Under ...
(Date:3/29/2017)... 29, 2017   Royal Philips (NYSE: ... technology, and PathAI, a company that develops artificial ... aim to develop solutions that improve the precision ... other diseases. The partnership aims to build deep ... of artificial intelligence to be applied to massive ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... Immunotherapy has emerged ... number of cancers and is touted to be the next revolution in our fight ... has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):